Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
ConclusionThe combination of JCAR014 with durvalumab for the treatment of adult pts with aggressive B-cell NHL appears safe; however, dose escalation is ongoing. Complete responses were observed both at initial restaging after JCAR014 infusion, and also subsequently in pts continuing durvalumab therapy after initially failing to achieve CR.DisclosuresHirayama: DAVA Oncology: Honoraria. Hay: DAVA Oncology: Honoraria. Till: Mustang Bio: Patents & Royalties, Research Funding. Kiem: Homology Medicine: Consultancy; Magenta: Consultancy; Rocket Pharmaceuticals: Consultancy. Shadman: Verastem: Consultancy; Beigene: Research Funding; Mustang Biopharma: Research Funding; Gilead Sciences: Research Funding; TG Therapeutics: Research Funding; AbbVie: Consultancy; Genentech: Research Funding; Pharmacyclics: Research Funding; Celgene: Research Funding; Qilu Puget Sound Biotherapeutics: Consultancy; Genentech: Consultancy; AstraZeneca: Consultancy; Acerta Pharma: Research Funding. Cassaday: Jazz Pharmaceuticals: Consultancy; Amgen: Consultancy, Research Funding; Merck: Research Funding; Seattle Genetics: Other: Spouse Employment, Research Funding; Pfizer: Consultancy, Research Funding; Adaptive Biotechnologies: Consultancy; Kite Pharma: Research Funding; Incyte: Research Funding. Acharya: Juno Therapeutics: Research Funding; Teva: Honoraria. Riddell: Cell Medica: Membership on an entity's Board of Directors or advisory committees; Juno Therapeutics: Equity Ownership, Patents & Royal...
Source: Blood - Category: Hematology Authors: Hirayama, A. V., Gauthier, J., Hay, K. A., Sheih, A., Cherian, S., Chen, X., Pender, B. S., Hawkins, R. M., Vakil, A., Steinmetz, R. N., Phi, T.-D., Chapuis, A. G., Till, B. G., Kiem, H.-P., Shadman, M., Cassaday, R. D., Acharya, U. H., Riddell, S. R., Ma Tags: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials: Poster I Source Type: research
More News: AstraZeneca | Autoimmune Disease | Biotechnology | Brain | Cancer & Oncology | Chemotherapy | Clinical Trials | CT Scan | Employment | Genetics | Hodgkin's Disease | Immunotherapy | Lymphoma | Merck | Neurology | Neuroscience | Non-Hodgkin's Lymphoma | PET Scan | Pfizer | Pharmaceuticals | Study | Toxicology